Host Defenses and Infectious Complications in Maintenance Hemodialysis Patients

  • Ann Rinehart
  • Allan J. Collins
  • William F. Keane


Prior to the advent of chronic hemodialysis, infection was a frequent terminal or pre-terminal event in patients with end-stage renal disease (ESRD). During the 1960s–1970s chronic hemodialysis therapy infectious complications resulted in significant morbidity and mortality, with up to one-third of deaths being attributable to infections (1, 2, 3, 4, 5). Despite improvement in dialysis and medical therapies, infection continues to account for a significant proportion (11 to 36%) of deaths in the chronic dialysis population (6, 7, 8, 9, 10, 11, 12, 13, 14). While this increased risk of infection is due to, in part, the necessity of blood access and/or complications of their underlying disease, there are abnormalities of the immune system in ESRD patients which may contribute to their predilection for infectious complications. In this chapter, we will review the incidence and types of infectious complications which occur in patients undergoing chronic hemodialysis, as well as outline our current understanding of the immune status of the dialysis patient. Quite importantly, the vast majority of infections are due to commonly occurring organisms, not opportunistic or unusual organisms, and repetitive exposure to infectious risk factors impacts on the types of infections observed


Peritoneal Dialysis Chronic Renal Failure Dialysis Patient Hemodialysis Patient Iron Overload 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Montgomerie JZ, Kalmanson GM, Guze LB: Renal failure and infection. Medicine 47: 1, 1968PubMedGoogle Scholar
  2. 2.
    Blagg CR, Hickman RO, Eschbach JW, Scribner BH: Home hemodialysis: six years’ experience. N Engl J Med 283: 1126, 1970PubMedCrossRefGoogle Scholar
  3. 3.
    Burton BT, Krueger KK, Bryan FA Jr: National registry of long-term dialysis patients. JAMA 218: 718, 1971PubMedGoogle Scholar
  4. 4.
    Gurland HJ, Brunner FP, Dehn Hv, Harlen H, Parsons FM, Schärer K: Combined report on regular dialysis and transplantation in Europe, III, 1972. Proc Eur Dial Transplant Assoc 10: XVII, 1973PubMedGoogle Scholar
  5. 5.
    Lowrie EG, Lazarus JM, Mocelin AJ, Bailey FL, Hampers CL, Wilson RE, Merrill JP: Survival of patients undergoing chronic hemodialysis and renal transplantation. N Engl J Med 288: 863, 1973PubMedCrossRefGoogle Scholar
  6. 6.
    Johnson WJ, Kurtz SB, Anderson CF, Mitchell JC, III, Zincke H, O’Fallon WM: Results of treatment of renal failure by means of home hemodialysis. Mayo Clin Proc 59: 663, 1984PubMedGoogle Scholar
  7. 7.
    Johnson WJ, Kurtz SB, Mitchell JC, III, VanDenBerg CJ, Wochos DN, O’Fallon WM, Sterioff S: Results of treatment of center hemodialysis patients. Mayo Clin Proc 59: 669, 1984PubMedGoogle Scholar
  8. 8.
    Santiago A, Chazan JA: Factors associated with mortality among 405 chronic hemodialysis patients who died between 1973 and 1985. (Abstract) Kidney Int 31: 245, 1987Google Scholar
  9. 9.
    Mailloux LU, Bellucci AG, Wilkes BM, Napolitano B, Mossey RT, Lesser M, Bluestone PA: Mortality in dialysis patients: analysis of the causes of death. Am J Kidney Dis 18: 326, 1991PubMedGoogle Scholar
  10. 10.
    Morduchowicz G, Winkler J, Derzane E, Van Dyk DF, Wittenberg C, Zabludowski JR, Shohat J, Rosenfeld JB, Boner G: Causes of death in patients with end-stage renal disease treated by dialysis in a center in Israel. Isr J Med Sci 28: 776, 1992PubMedGoogle Scholar
  11. 11.
    Port FK: Mortality and causes of death in patients with end-stage renal failure. Am J Kidney Dis 15: 215, 1990PubMedGoogle Scholar
  12. 12.
    Kjellstrand CM, Fryd D, Najarian JS: Late deaths on dialysis and transplantation therapy. Contrib Nephrol 70: 64, 1989PubMedGoogle Scholar
  13. 13.
    Fernandez JM, Carbonell ME, Mazzuchi N, Petruccelli D: Simultaneous analysis of morbidity and mortality factors in chronic hemodialysis patients. Kidney Int 41: 1029, 1992PubMedGoogle Scholar
  14. 14.
    Khan IH, Catto GRD: Long-term complications of dialysis: infection. Kidney Int 43(Suppl 41): S143, 1993Google Scholar
  15. 15.
    Hume DM, Merrill JP, Miller BF, Thorn GW: Experiences with renal homotransplantation in humans. Report of nine cases. J Clin Invest 32: 327, 1955Google Scholar
  16. 16.
    Mannick JA, Powers JH, Mithoefer J, Ferrebee JW: Renal transplantation in azotemic dogs. Surgery 47: 340, 1960PubMedGoogle Scholar
  17. 17.
    Dammin GJ, Couch NP, Murray JE: Prolonged survival of skin homografts in uremia patients. Ann N Y Acad Sci 64: 967, 1957PubMedGoogle Scholar
  18. 18.
    Smiddy FG, Burwell RG, Parsons FM: The effect of acute uraemia upon the survival of skin homografts. The influence of uraemia upon certain aspects of lymph-node reactivity. Br J Surg 48: 328, 1960Google Scholar
  19. 19.
    Morrison AB, Maness K, Tawes R: Skin homograft survival in chronic renal insufficiency. Arch Pathol 75: 139, 1963Google Scholar
  20. 20.
    London WT, DiFiglia M, Sutnick AI, Blumberg BS: An epidemic of hepatitis in a chronic hemodialysis unit: Australia antigen and differences in host response. N Engl J Med 281: 571, 1969PubMedCrossRefGoogle Scholar
  21. 21.
    London WT, Drew JS, Lustbader ED, Werner BG, Blumberg BS: Host responses to hepatitis B infection in patients in a chronic hemodialysis unit. Kidney Int 12: 51, 1977PubMedGoogle Scholar
  22. 22.
    Ribot S, Rothstein M, Goldblatt M, Grasso M: Duration of hepatitis B surface antigenemia (HBsAg) in hemodialysis patients. Arch Intern Med 139: 178, 1979PubMedGoogle Scholar
  23. 23.
    Szmuness W, Prince AM, Grady GF, Mann MK, Levine RW, Friedman EA, Jacobs MJ, Josephson A, Ribot S, Shapiro FL et al.: Hepatitis B infection. A pointprevalance study in 15 US hemodialysis centers. JAMA 227: 901, 1974PubMedGoogle Scholar
  24. 24.
    Matas AJ, Simmons RL, Kjellstrand CM, Buselmeier TJ, Najarian JS: Increased incidence of malignancy during chronic renal failure. Lancet 1: 883, 1975PubMedGoogle Scholar
  25. 25.
    Sutherland GA, Glass J, Gabriel R: Increased incidence of malignancy in chronic renal failure. Nephron 18: 182, 1977PubMedGoogle Scholar
  26. 26.
    Lindner A, Farewell YJ, Sherrard DJ: High incidence of neoplasia in uremic patients receiving long-term dialysis. Nephron 27: 292, 1981PubMedGoogle Scholar
  27. 27.
    Degoulet P, Reach I, Jacobs C: Cancer in patients on hemodialysis. N Engl J Med 300: 1279, 1979PubMedGoogle Scholar
  28. 28.
    Coplon NS, Diskin CJ, Peterson J, Sivenson RS. The long-term clinical course of systemic lupus erythematosus in end-stage renal disease. N Engl J Med 308: 186, 1983PubMedCrossRefGoogle Scholar
  29. 29.
    Hosking CS, Atkins RC, Scott DF, Holdsworth SR, Fitzgerald MG, Shelton MJ: Immune and phagocytic function in patients on maintenance dialysis and posttransplantation. Clin Nephrol 6: 501, 1976PubMedGoogle Scholar
  30. 30.
    Casciani CU, DeSimone C, Bonini S, Gallucci MT, Matteucci G, Valesini G, Meli D, Masala C: Immunological aspects of chronic uremia. Kidney Int 13(Suppl 8): S49, 1978Google Scholar
  31. 31.
    Raskova J, Ghobrial I, Czerwinski DK, Shea SM, Eisinger RP, Raska K Jr: B-cell activation and immunoregulation in end-stage renal disease patients receiving hemodialysis. Arch Intern Med 147: 89, 1987PubMedGoogle Scholar
  32. 32.
    Quadracci LJ, Ringdén O, Krzymanski M: The effect of uremia and transplantation on lymphocyte subpopulations. Kidney Int 10: 179, 1976PubMedGoogle Scholar
  33. 33.
    Hoy WE, Cestero RVM, Freeman RB: Deficiency of T and B lymphocytes in uremic subjects and partial improvement with maintenance hemodialysis. Nephron 20: 182, 1978PubMedGoogle Scholar
  34. 34.
    Gagnon RF, Shuster J, Kaye M: Auto-immunity in patients with end-stage renal disease maintained on hemodialysis and continuous ambulatory peritoneal dialysis. J Clin Lab Immunol 11: 155, 1983PubMedGoogle Scholar
  35. 35.
    Howell ED, Perkins HA: Anti-N-like antibodies in the sera of patients undergoing chronic hemodialysis. Vox Sang 23: 291, 1972PubMedGoogle Scholar
  36. 36.
    Crosson JT, Moulds J, Comty CM, Polesky HF: A cl inical study of anti-NDP in the sera of patients in a large repetitive hemodialysis program. Kidney Int 10: 463, 1976PubMedGoogle Scholar
  37. 37.
    Kaehny WD, Miller GE, White WL: Relationship between dialyzer reuse and the presence of anti-N-like antibodies in chronic hemodialysis patients. Kidney Int 12: 59, 1977PubMedGoogle Scholar
  38. 38.
    Nolph KD, Husted FC, Sharp GC, Siemsen AW: Antibodies to nuclear antigens in patients undergoing long-term hemodialysis. Am J Med 60: 673, 1976PubMedGoogle Scholar
  39. 39.
    Balch HH: The effect of severe battle injury and posttraumatic renal failure on resistance to infection. Ann Surg 142: 145, 1955PubMedGoogle Scholar
  40. 40.
    Stoloff IL, Stout R, Myerson RM, Havens WP Jr: Production of antibody in patients with uremia. N Engl J Med 259: 320, 1958PubMedCrossRefGoogle Scholar
  41. 41.
    Wilson WEC, Kirkpatrick CH, Talmage DW: Suppression of immunologic responsiveness in uremia. Ann Intern Med 621: 1, 1965Google Scholar
  42. 42.
    Boulton-Jones JM, Vick R, Cameron JS, Block PH: Immune responses in uremia. ClinNephrol 1: 351, 1973Google Scholar
  43. 43.
    Byron PR, Mallick NP, Taylor G: Immune potential in human uraemia. I. Relationship of glomerular filtration rate to depression of immune potential. J Clin Path 29: 765, 1976PubMedGoogle Scholar
  44. 44.
    Byron PR, Mallick NP, Taylor G: Immune potential in human uraemia. 2. Changes after regular haemodialysis therapy. J Clin Path 29: 770, 1976PubMedGoogle Scholar
  45. 45.
    Jordan MC, Rousseau WE, Tegtmeier GE, Noble GR, Muth RG, Chin TDY: Immunogenicity of inactivated influenza virus vaccine in chronic renal failure. Ann Intern Med 79: 790, 1973PubMedGoogle Scholar
  46. 46.
    Ortbals DW, Marks ES, Liebhaber H: Influenza immunization in patients with chronic renal disease. JAMA 239: 2562, 1978PubMedGoogle Scholar
  47. 47.
    Osanloo EO, Berlin BS, Popli S, Ing TS, Cummings JE, Ghandi VC, Geis WP, Hano JE: Antibody responses to influenza vaccination in patients with chronic renal failure. Kidney Int 14: 614, 1978PubMedGoogle Scholar
  48. 48.
    Pabico RC, Douglas RG, Betts RF, McKenna BA, Freeman RB: Influenza vaccination of patients with glomerular diseases. Effects on creatinine clearance, urinary protein excretion, and antibody response. Ann Intern Med 81: 171, 1974PubMedGoogle Scholar
  49. 49.
    Simberkoff MS, Schiffman G, Katz LA, Spicehandler JR, Moldover NH, Rahal J Jr: Pneumococcal capsular polysaccharide vaccination in adult chronic hemodialysis patients. J Lab Clin Med 96: 363, 1980PubMedGoogle Scholar
  50. 50.
    Linnemann CC Jr, First MR, Schiffman G: Response to pneumococcal vaccine in renal transplant and hemodialysis patients. Arch Intern Med 141: 1637, 1981PubMedGoogle Scholar
  51. 51.
    Nikoskelainen J, Koskela M, Forsström J, Kasanen A, Leinonen M: Persistence of antibodies to pneumococcal vaccine in patients with chronic renal failure. Kidney Int 28: 672, 1985PubMedGoogle Scholar
  52. 52.
    Rytel MW, Dailey MP, Schiffman G. Hoffman RG, Piering WF: Pneumococcal vaccine immunization of patients with renal impairment. Proc Soc Exp Biol Med 182: 468, 1986PubMedGoogle Scholar
  53. 53. Update: Pneumococcal polysaccharide vaccine usage — United States. Recommendations of the Immunization Practices Advisory Committee. Ann Intern Med 101: 348, 1984Google Scholar
  54. 54.
    Linnemann CC, First MR, Schiffman G: Revaccination of renal transplant and hemodialysis recipients with pneumococcal vaccine. Arch Intern Med 146: 1554, 1986PubMedGoogle Scholar
  55. 55.
    Stevens CE, Szmuness W, Goodman AI, Weseley SA, Fotino M: Hepatitis B vaccine: immune responses in haemodialysis patients. Lancet 2: 1211, 1980PubMedGoogle Scholar
  56. 56.
    Crosnier J, Jungers P, Courouce AM, Laplanchei A, Benhamou E, Degos F, Lacour B, Prunet P, Cerisier V, Guesry P: Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: II, haemodialysis patients. Lancet 1: 797, 1981PubMedGoogle Scholar
  57. 57.
    Stevens CE, Alter HJ, Taylor PE, Zang EA, Harley EJ, Szmuness W, and the dialysis vaccine trial stydy group: Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N Engl J Med 311: 496, 1984PubMedCrossRefGoogle Scholar
  58. 58.
    Desmyter J, Colaert J, DeGroote G, Reynders M, Reerink-Brongers EE, Lelie PN, Dees PJ, Reesink HW, and the Leuven renal transplantation collaborative group: Efficacy of heat-inactivated hepatitis B vaccine in haemodialysis patients and staff. Lancet 2: 1323, 1983PubMedGoogle Scholar
  59. 59.
    Benhamou E, Courouce AM, Jungers P, Laplanche A, Degos F, Brangier J, Crosnier J: Hepatitis B vaccine: randomized trial of immunogenicity in hemodialysis patients. Clin Nephrol 21: 143, 1984PubMedGoogle Scholar
  60. 60.
    Köhler H, Arnold W, Renschin G, Dormeyer HH, Zum Buschenfelde KHM: Active hepatitis B vaccination of dialysis patients and medical staff. Kidney Int 25: 124, 1984PubMedGoogle Scholar
  61. 61.
    de Graeff PA, Dankert J, de Zeeuw D, Gips CH, van der Hem GK: Immune response to two different hepatitis B vaccines in haemodialysis patients: a 2-year follow-up. Nephron 40: 155, 1985PubMedGoogle Scholar
  62. 62.
    Benhamou E, Courouce AM, Laplanche A, Jungers P, Tron JF, Crosnier J: Long-term results of hepatitis B vaccination in patients on dialysis. N Engl J Med 314: 1710. 1986PubMedGoogle Scholar
  63. 63.
    Kunori T, Fehrman I, Ringdén O, Möller E: In vitro characterization of immunological responsiveness of uremic patients. Nephron 26: 234, 1980PubMedGoogle Scholar
  64. 64.
    Kurz P, Köhler H, Meuer S, Hütteroth T, Zum Büschenfelde KHM: Impaired cellular immune responses in chronic renal failure: evidence for a T cell defect. Kidney Int 29: 1209, 1986PubMedGoogle Scholar
  65. 65.
    Osaki K, Otsuka H, Uomizu K, Harada R, Otsuji Y, Hashimoto S: Monocyte-mediated suppression of mitogen responses of lymphocytes in uremid patients. Nephron 34: 87, 1983PubMedGoogle Scholar
  66. 66.
    Gaciong Z, Alexiewicz JM, Linker-Israeli M, Shulman I, Pitts TO, Massry SG: Inhibition of immunoglobulin production by parathyroid hormone. Implications in chronic renal failure. Kidney Int 40: 96, 1991PubMedGoogle Scholar
  67. 67.
    Huber H, Pastner D, Dittrich P, Braunsteiner H: In vitro reactivity of human leukocytes in uraemia — a comparison with the impairment of delayed hypersensitivity. Clin Exp Immunol 5: 75, 1969PubMedGoogle Scholar
  68. 68.
    Selroos O, Pasternack A, Virolainen M: Skin test sensitivity and antigen-induced lymphocyte transformation in uraemia. Clin Exp Immunol 14: 365, 1973PubMedGoogle Scholar
  69. 69.
    Elves MW, Israëls MCG, Collinge M: An assessment of the mixed leucocyte reaction in renal failure. Lancet 1: 682, 1966PubMedGoogle Scholar
  70. 70.
    Sengar DPS, Hyslop DB, Rashid A, Harris JE: T-rosettes in hemodialysis patients and renal allograft recipients. Cell Immunol 20: 92, 1975PubMedGoogle Scholar
  71. 71.
    Kauffman CA, Manzler AD, Phair JP: Cell-mediated immunity in patients on long-term haemodialysis. Clin Exp Immunol 22: 54, 1975PubMedGoogle Scholar
  72. 72.
    Kamata K, Okubo M, Sada M: Immunosuppressive factors in uraemic sera are composed of both dialysable and non-dialysable components. Clin Exp Immunol 54: 277, 1983PubMedGoogle Scholar
  73. 73.
    Holdsworth SR, Fitzgerald MG, Hosking CS, Atkins RC: The effect of maintenance dialysis on lymphocyte function. I. Haemodialysis. Clin Exp Immunol 33: 95, 1978PubMedGoogle Scholar
  74. 74.
    Donati D, Degiannis D, Raskova J, Raska K: Uremic serum effects on peripheral blood mononuclear cell and purified T lymphocyte responses. Kidney Int 42: 681, 1992PubMedGoogle Scholar
  75. 75.
    Silk MR: The effect of uremic plasma on lymphocyte transformation. Invest Urol 5: 195, 1967PubMedGoogle Scholar
  76. 76.
    Newberry WM, Sanford JP: Defective cellular immunity in renal failure: depression of reactivity of lymphocytes to phytohemagglutinin by renal failure serum. J Clin Invest 50: 1262, 1971PubMedGoogle Scholar
  77. 77.
    Sengar DPS, Rashid A, Harris JE: In vitro reactivity of lymphocytes obtained from uraemic patients maintained on haemodialysis. Clin Exp Immunol 21: 298, 1975PubMedGoogle Scholar
  78. 78.
    Asaka M, Iida H, Izumino K, Sasayama S: Depressed natural killer cell activity in uremia. Nephron 49: 291, 1988PubMedGoogle Scholar
  79. 79.
    Nakhla LS, Goggin MJ: Lymphocyte transformation in chronic renal failure. Immunology 24: 229, 1973PubMedGoogle Scholar
  80. 80.
    Fehrman I, Ringdén O, Bergström J: MLC-blocking factors in uremic sera. Clin Nephrol 14: 183, 1980PubMedGoogle Scholar
  81. 81.
    Slavin RG, Fitch CD: Inhibition of lymphocyte transformation by guanidinosuccinic acid, a surplus metabolite in uremia. Experientia 27: 1340, 1971PubMedGoogle Scholar
  82. 82.
    Hanicki Z, Cichocki T, Sarnecka-Keller M, Klein A, Komorowska Z: Influence of middle-sized molecule aggregates from dialysate of uremic patients on lymphocyte transformation in vitro. Nephron 17: 73, 1976PubMedGoogle Scholar
  83. 83.
    Harris JE, Page D, Posen G, Stewart T. Suppression of in vitro lymphocyte function by uremic toxins. J Urol 108: 312, 1972PubMedGoogle Scholar
  84. 84.
    Raska K Jr, Morrison AB, Raskova J: Humoral inhibitors of the immune response in uremia. III. The immunosuppressive factor of uremic rat serum is a very low density lipoprotein. Lab Invest 42: 636, 1980PubMedGoogle Scholar
  85. 85.
    Stewart E, Miller TE: Host immune status in uraemia. II. Serum factors and lymphocyte transformation. Clin Exp Immunol 41: 123, 1980PubMedGoogle Scholar
  86. 86.
    Mezzano S, Pesce AJ, Pollak VE, Michael JG: Analysis of humoral and cellular factors that contribute to impaired immune responsiveness in experimental uremia. Nephron 36: 15, 1984PubMedCrossRefGoogle Scholar
  87. 87.
    Raskova J, Morrison AB: A decrease in cell-mediated immunity in uremia associated with an increase in activity of suppressor cells. Am J Pathol 84: 1, 1976PubMedGoogle Scholar
  88. 88.
    Alevy YG, Slavin RG, Hutcheson P: Immune response in experimentally induced uremia. I. Suppression in mitogen responses by adherent cells in chronic uremia. Clin Immunol Immunopathol 19: 8, 1981PubMedGoogle Scholar
  89. 89.
    Raskova J, Raska K: Humoral inhibitors of the immune response in uremia. V. Induction of suppressor cells in vitro by uremic serum. Am J Pathol 111: 149, 1983PubMedGoogle Scholar
  90. 90.
    Lortran JE, Kiepiela P, Coovadia HM, Seedat YK: Suppressor cells assayed by numerical and functional tests in chronic renal failure. Kidney Int 22: 192, 1982Google Scholar
  91. 91.
    Raska Jr, Raskova J, Shea SM, Frankel RM, Wood RH, Lifter J, Ghobrial I, Eisinger RP, Homer L: T cell subsets and cellular immunity in end-stage renal disease. Am J Med 75: 734, 1983PubMedGoogle Scholar
  92. 92.
    Chida Y, Sakurai S, Yoshiyama N: The effect of hemodialysis on lymphocyte subsets during dialysis. Clin Nephrol 25: 159, 1986PubMedGoogle Scholar
  93. 93.
    Chatenoud L, Dugas B, Beaurain G, Touam M, Drüeke T, Vasquez A, Galanaud P, Bach JF, DelFraissy JF: Presence of preactivated T cells in hemodialyzed patients: their possible role in altered immunity. Proc Natl Acad Sci USA 83: 7457, 1986PubMedGoogle Scholar
  94. 94.
    Raskova J, Ghobrial I, Shea SM, Eisinger RP, Raska K: Suppressor cells in end-stage renal disease. Functional assays and monoclonal antibody analysis. Am J Med 76: 847, 1984PubMedGoogle Scholar
  95. 95.
    Guillon PJ, Woodhouse LF, Davison AM, Giles GR: Suppressor cell activity of peripheral mononuclear cells from patients undergoing chronic hemodialysis. Biomedicine 32: 11, 1980Google Scholar
  96. 96.
    Ruddy MC, Rubin AL, Novogrodsky A, Stenzel K: Decreased macrophage-mediated suppression of lymphocyte activation in chronic renal failure. Am J Med 75:571, 1983PubMedGoogle Scholar
  97. 97.
    Tsakolos ND, Theoharides TC, Herdler ED, Guffinet J, Dwyer JM, Whisler HL, Askenase PW: Immune defects in chronic renal impairment: evidence for defective regulation of lymphocyte response by macrophages from patients with chronic renal impairment on haemodialysis. Clin Exp Immunol 63: 218, 1986PubMedGoogle Scholar
  98. 98.
    Kleiman KS, Zoschke DC: Suppression of human lymphocyte responses in chronic renal failure mediated by adherent cells: analysis in serum-free media. J Lab Clin Med 106: 262, 1985PubMedGoogle Scholar
  99. 99.
    Waltzer WC, Bachvaroff RJ, Raisbeck AP, Egelandsdal B, Pullis C, Shen L, Rapaport FT: Immunologic monitoring in patients with end-stage renal disease. J Clin Immunol 4: 364, 1984PubMedGoogle Scholar
  100. 100.
    Sanders Jr, Luby JP, Sanford JP, Hull AR: Suppression of interferon response in lymphocytes from patients with uremia. J Lab Clin Med 77: 768, 1971PubMedGoogle Scholar
  101. 101.
    Gál G, Toth M, Toth S: Interferon production by leukocytes of dialysed chronic uraemic patients. Proc Eur Dial Transplant Assoc 18: 188, 1981PubMedGoogle Scholar
  102. 102.
    Schindler R, Linnenweber S, Schulze M, Oppermann M, Dinarello CA, Shaldon S, Koch KM: Gene expression of interleukein-1β during hemodialysis. Kidney Int 43: 712, 1993PubMedGoogle Scholar
  103. 103.
    Dinarello CA: Interleukin-1 and tumor necrosis factor and their naturally occurring antagonists during hemodialysis. Kidney Int 42(Suppl 38): S68, 1992Google Scholar
  104. 104.
    Ureña P, Herbelin A, Zingraff J, Lair M, Man NK, Descamps-Latscha B, Drueke T: Permeability of cellulosic and non-cellulosic membranes to endotoxin subunits and cytokine production during in-vitro haemodialysis. Nephrol Dial Transplant 7: 16, 1992PubMedGoogle Scholar
  105. 105.
    Luger A, Kovarik J, Stummvoll HK, Urbanska A, Luger TA: Blood-membrane interaction in hemodialysis leads to increased cytokine production. Kidney Int 32: 84, 1987PubMedGoogle Scholar
  106. 106.
    Herbelin A, Nguyen AT, Zingraff J, Urena P, Descamps-Latscha B: Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor α. Kidney Int 37: 116, 1990PubMedGoogle Scholar
  107. 107.
    Bingel M, Lonnemann G, Shaldon S, Koch KM, Dinarello CA: Human interleukin-1 production during hemodialysis. Nephron 43: 161, 1986PubMedGoogle Scholar
  108. 108.
    Lonnemann G, Koch KM, Shaldon S: Induction of interleukin-1 (IL-1) from human monocytes adhering to hemodialysis (HD) membranes. (Abstract) Kidney Int 31: 238, 1987Google Scholar
  109. 109.
    Shaldon S, Bingel M, Lonnemann G, Dinarello CA, Koch KM: Human interleukin-1 (IL-1) production is enhanced by sodium acetate. Abstracts Am Soc Artif Intern Organs 16: 33, 1987Google Scholar
  110. 110.
    Betz M, Haensch GM, Rauterberg EW, Bommer J, Ritz E: Cuprammonium membranes stimulate interleukin 1 release and arachidonic acid metabolism in monocytes in the absence of complement. Kidney Int 34: 67, 1988PubMedGoogle Scholar
  111. 111.
    Ryan JJ, Beynon HLC, Rees AJ, Cassidy MJD: In vitro production of tumor necrosis factor by monocytes cultured from dialysis patients. Kidney Int 43(Suppl 41): S226, 1993Google Scholar
  112. 112.
    Roccatello D, D’Alfonso S, Peruccio D, Quattrocchio G, Cavalli G, Isidoro C, Piccoli G, Richiardi PM: Induction of mRNA for tumor necrosis factor a in hemodialysis. Kidney Int 43(Suppl 39): S144, 1993Google Scholar
  113. 113.
    Descamps-Latscha B, Herbelin A, Nguyen AT, De Groote D, Chauveau P, Verger C, Jungers P, Zingraff J: Soluble CD23 as an effector of immune dysregulation in chronic uremia and dialysis. Kidney Int 43: 878, 1993PubMedGoogle Scholar
  114. 114.
    Pertosa G, Tarantino EA, Gesualdo L, Montinaro V, Schena FP: C5b-9 generation and cytokine production in hemodialyzed patients. Kidney Int 43(Suppl 41): S221, 1993Google Scholar
  115. 115.
    Brockhaus M, Bar-Khayim Y, Gurwicz S, Frensdorff A, Haran N: Plasma tumor necrosis factor soluble receptors in chronic renal failure. Kidney Int 42: 663, 1992PubMedGoogle Scholar
  116. 116.
    Pertosa G, Gesualdo L, Tarantino EA, Ranieri E, Bottalico D, Schena FP: Influence of hemodialysis on interleukin-6 production and gene expression by peripheral blood mononuclear cells. Kidney Int 43(Suppl 39): S149, 1993Google Scholar
  117. 117.
    Cavaillon JM, Poigner JL, Fitting C, Delons S: Serum interleukin-6 in long-term hemodialyzed patients. Nephron 60: 307, 1992PubMedCrossRefGoogle Scholar
  118. 118.
    Herbelin A, Urena P, Nguyen AT, Zingraff J, Descamps-Latscha B: Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int 39: 954, 1991PubMedGoogle Scholar
  119. 119.
    Cala S, Mazuran R, Kordic D: Negative effect of uraemia and cuprophane haemodialysis on natural killer cells. Nephrol Dial Transplant 5: 437, 1990PubMedGoogle Scholar
  120. 120.
    Pisa P, Jira M, Horky J, Strejcek J, Valek A: Depression in spontaneous cell-mediated cytotoxicity occurs during hemodialysis. Clin Nephrol 27: 289, 1987PubMedGoogle Scholar
  121. 121.
    Zaoui P, Hakim RM: Natural killer-cell function in hemodialysis patients: effect of the dialysis membrane. Kidney Int 43: 1298, 1993PubMedGoogle Scholar
  122. 122.
    Ringoir S, VanLooy L, Van de Heyning P, Leroux-Roels G: Impairment of phagocytic activity of macrophages as studied by the skin window test in patients on regular hemodialysis treatment. Clin Nephrol 4: 234, 1975PubMedGoogle Scholar
  123. 123.
    Hanicki Z, Cichocki T, Komorowska Z, Sulowicz W, Smolenski O: Some aspects of cellular immunity in untreated and maintenance hemodialysis patients. Nephron 23: 273, 1979PubMedGoogle Scholar
  124. 124.
    Urbanitz D, Sieberth HG: Impaired phagocytic activity of human monocytes in respect to reduced antibacterial resistance in uremia. Clin Nephrol 4: 13, 1975PubMedGoogle Scholar
  125. 125.
    Jorstad S, Viken KE: Inhibitory effects of plasma from uraemic patients on human mononuclear phagocytes cultured in vitro. Acta Pathol Microbiol Scand (C) 85: 169, 1977Google Scholar
  126. 126.
    Jorstad S, Kvernes S: Uraemic toxins of high molecular weight inhibiting human mononuclear phagocytes cultured in vitro. Acta Pathol Microbiol Scand (C) 86: 221, 1978Google Scholar
  127. 127.
    Alevy YG, Mueller KR, Slavin RG: Immune response in experimentally induced uremia. VI. Uremic macrophages are defective in their ability to present antigen to T cells. Clin Immunol Immunopathol 29: 433, 1983PubMedGoogle Scholar
  128. 128.
    Gibbons R, Martinez O, Lim V, Garovoy MR: Defective antigen presentation in uremia: a monocyte defect. Kidney Int 31: 232, 1987Google Scholar
  129. 129.
    Lewis SL, Van Epps DE, Chenoweth DE: C5a receptor modulation on neutrophils and monocytes from chronic hemodialysis and peritoneal dialysis patients. Clin Nephrol 26: 37, 1986PubMedGoogle Scholar
  130. 130.
    Keane WF, Comty CM, Verbrugh HA, Peterson PK: Opsonic deficiency of peritoneal dialysis effluent in continuous ambulatory peritoneal dialysis. Kidney Int 25: 539, 1984PubMedGoogle Scholar
  131. 131.
    Keane WF, Peterson PK: Host defense mechanisms of the peritoneal cavity and continuous ambulatory peritoneal dialysis. Perit Dial Bull 4: 122, 1984Google Scholar
  132. 132.
    Goldstein CS, Bomalaski JS, Zurier RB, Neilson EG, Douglas SD: Analysis of peritoneal macrophages in continuous peritoneal dialysis patients. Kidney Int 26: 733, 1984PubMedGoogle Scholar
  133. 133.
    Duwea K, Vas SI, Weatherhead JW: The effect of the composition of peritoneal dialysis fluid on chemiluminescence phagocytosis and bactericidal activity in vitro. Infect Immun 33: 130, 1981Google Scholar
  134. 134.
    Harvey DM, Sheppard KJ, Morgan AG, Fletcher J: Effect of dialysate fluids on phagocytosis and killing by normal neutrophils. J Clin Microbiol 25: 1424, 1987PubMedGoogle Scholar
  135. 135.
    Carozzi S, Nasini MG, Schelotto C, Caviglia PM, Barocci S, Cantaluppi A, Salit M: Peritoneal dialysis fluid (PDF) C++ and 1,25(OH)2D3 modulate peritoneal macrophage (PMO) antimicrobial activity in CAPD patients. Adv Perit Dial 6: 110, 1990PubMedGoogle Scholar
  136. 136.
    Carozzi S, Nasini MG, Cantaluppi A: Effects of longterm therapy with low Ca++ peritoneal dialysis solution (PDS) and I. P. 1,25(OH)2D3 (VD3) on peritoneal immune defense mechanisms in CAPD. (Abstract) Perit Dial Int 11(Suppl 1): 42, 1991Google Scholar
  137. 137.
    Piraino B, Bernardini J, Holley JL, Perlmutter JA: Increased risk of staphylococcus epidermidis peritonitis in patients on dialysate containing 1.25 mmol/l calcium. Am J Kidney Dis 19: 371, 1992PubMedGoogle Scholar
  138. 138.
    Peterson PK, Gaziano E, Devalon M, Peterson LA, Keane WF: Antimicrobial activities of dialysate elicited and resident human peritoneal macrophages. Infect Immun 49: 212, 1985PubMedGoogle Scholar
  139. 139.
    Peterson PK, Lee D, Suh HJ, Devalon M, Nelson RD, Keane WF: Intracellular survival of Candida albicans in peritoneal macrophages from chronic peritoneal dialysis patients. Am J Kidney Dis 7: 146, 1986PubMedGoogle Scholar
  140. 140.
    Kleinman MF, Doehring RO, Furman KI et al.: Frontiers in peritoneal dialysis. in Importance of Intracellular Organisms in CAPD, edited by Maher JF, Winchester JF, New York, Field, Rich and Assoc, 1986, p 546Google Scholar
  141. 141.
    Verbrugh HA, Van Bronswizk H, Lien P: The fate of phagocytized Staphylococcus epidermidis: survival and growth in human mononuclear phagocytes as a potential pathogenic mechanism. in Pathogenicity and Clinical Significance of Coagulasenegative Staphylococci, edited by Pulverer G, Quie PG, Peters G, New York/Stuttgart, Gustav Fischer Verlag, 1987, p 55Google Scholar
  142. 142.
    Buggy BP, Schaberg DR, Swartz RD: Intraleukocyte sequestration as a cause of persistent Staphylococcus aureus peritonitis in continuous ambulatory peritoneal dialysis. Am J Med 76: 1035, 1984PubMedGoogle Scholar
  143. 143.
    Lamperi S, Carozzi S: Defective opsonic activity of peritoneal effluent during continuous ambulatory peritoneal dialysis (CAPD): importance and prevention. Perit Dial Bull 6: 87, 1986Google Scholar
  144. 144.
    Lamperi S, Carozzi S: Suppressor resident peritoneal macrophages and peritonitis incidence in continuous ambulatory peritoneal dialysis. Nephron 44: 219, 1986PubMedGoogle Scholar
  145. 145.
    Jensson O: Observations on the blood leukocytes in chronic renal insufficiency. Br J Haematol 4: 422, 1958PubMedGoogle Scholar
  146. 146.
    Riis P, Stougaard J: The peripheral blood leukocytes in chronic renal insufficiency. Dan Med Bull 6: 85, 1959PubMedGoogle Scholar
  147. 147.
    Vincent PC, Sutherland R, Morris TCM, Chapman GV: Inhibitor of in vitro granulopoiesis in plasma of patients with renal failure. Lancet 2: 864, 1978PubMedGoogle Scholar
  148. 148.
    Craddock PR, Fehr J, Dalmasso AP, Brigham KL, Jacob HS: Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes. J Clin Invest 59: 879, 1977PubMedGoogle Scholar
  149. 149.
    Peresecenschi G, Blum M, Aviram A, Spirer ZH: Impaired neutrophil response to acute bacterial infection in dialyzed patients. Arch Intern Med 141: 1301, 1981PubMedGoogle Scholar
  150. 150.
    Brayton RG, Stokes PE, Schwartz MS, Louria DB: Effect of alcohol and various diseases on leukocyte mobilization, phagocytosis and intracellular bacterial killing. N Engl J Med 282: 123, 1970PubMedCrossRefGoogle Scholar
  151. 151.
    Buchanan WW, Klinenberg JR, Seegmiller JE: The inflammatory response to injected microcrystalline monosodium urate in normal hyperuremic, gouty and uremic subjects. Arthritis Rheum 8: 361, 1968Google Scholar
  152. 152.
    Abrutyn E, Solomons NW, St Clair L, MacGregor RR, Root RK: Granulocyte function in patients with chronic renal failure: surface adherence, phagocytosis and bactericidal activity in vitro. J Infect Dis 135: 1, 1977PubMedGoogle Scholar
  153. 153.
    Lespier-Dexter LE, Guerra C, Ojeda W, Martinez-Maldonado M: Granulocyte adherence in uremia and hemodialysis. Nephron 24: 64, 1979PubMedGoogle Scholar
  154. 154.
    Salant DJ, Glover AM, Anderson R, Meyers AM, Rabkin R, Myburgh JA, Rabson AR: Depressed neutrophil chemotaxis in patients with chronic renal failure and after renal transplantation. J Lab Clin Med 88: 536, 1976PubMedGoogle Scholar
  155. 155.
    Siriwatratananonta P, Sinsakul V, Stern K, Slavin RG: Defective chemotaxis in uremia. J Lab Clin Med 92: 402, 1978PubMedGoogle Scholar
  156. 156.
    Greene WH, Ray C, Mauer SM, Quie PG: The effect of hemodialysis on neutrophil chemotactic responsiveness. J Lab Clin Med 88: 971, 1976PubMedGoogle Scholar
  157. 157.
    Björkstén B, Mauer SM, Mills EL, Quie PG: The effect of hemodialysis on neutrophil chemotactic responsiveness. Acta Med Scand 203: 67, 1978PubMedCrossRefGoogle Scholar
  158. 158.
    Goldblum SE, Van Epps DE, Reed WP: Serum inhibitor of C5 fragment-mediated polymorphonuclear leukocyte chemotaxis associated with chronic hemodialysis. J Clin Invest 64: 255, 1979PubMedGoogle Scholar
  159. 159.
    Modai D, Weissgarten J, Zolf R, Peller S, Averbukh Z, Kaufman S, Shaked U, Cohen N, Golik A, Tieder M: Effect of levamisole on chemotaxis of granulocytes from uremic patients. Nephron 49: 237, 1988PubMedGoogle Scholar
  160. 160.
    Charpentier B, Lang P, Martin B, Noury J, Mathieu D, Fries D: Depressed polymorphonuclear leukocyte functions associated with normal cytotoxic functions of T and natural killer cells during chronic hemodialysis. Clin Nephrol 19: 288, 1983PubMedGoogle Scholar
  161. 161.
    Hällgren R, Fjellström KE, Håkansson L, Venge P: The serum-independent uptake of IgG-coated particles by polymorphonuclear leukocytes from uremic patients on regular dialysis treatment. J Lab Clin Med 94: 277, 1979PubMedGoogle Scholar
  162. 162.
    Montgomerie JZ, Kalmanson GM, Guze LB: Leukocyte phagocytosis and serum bactericidal activity in chronic renal failure. Am J Med Sci 264: 385, 1972PubMedGoogle Scholar
  163. 163.
    Hirabayashi Y, Kobayashi T, Nishikawa A, Okazaki H, Aoki T, Takaya J, Kobayashi Y: Oxidative metabolism and phagocytosis of polymorphonuclear leukocytes in patients with chronic renal failure. Nephron 49: 305, 1988PubMedGoogle Scholar
  164. 164.
    Cantinieaux B, Boelaert J, Hariga C, Fondu P: Impaired neutrophil defense against Yersinia enterocolitica in patients with iron overload who are undergoing dialysis. J Lab Clin Med 111: 524, 1988PubMedGoogle Scholar
  165. 165.
    Boelaert JR, Cantinieaux BF, Hariga CF, Fondu PG: Recombinant erythropoietin reverses polymorphonuclear granulocyte dysfunction in iron-overloaded dialysis patients. Nephrol Dial Transplant 5: 504, 1990PubMedGoogle Scholar
  166. 166.
    Haag-Weber M, Hable M, Schollmeyer P, Hörl WH: Metabolic response of neutrophils to uremia and dialysis. Kidney Int 36: S293, 1989Google Scholar
  167. 167.
    Aparicio M, Vincendeau P, Gin H, Potaux L, Boucher JL, Martin-Dupont P, Morel D, dePrecigout V, Bezian JH: Effect of a low-protein diet on chemiluminescence production by leukocytes from uremic patients. Nephron 48: 315, 1988PubMedGoogle Scholar
  168. 168.
    Chandra RK: Rosette-forming T lymphocytes and cellmediated immunity in malnutrition. Br Med J 3: 608, 1974PubMedGoogle Scholar
  169. 169.
    Vanholder R, Van Biesen W, Ringoir S: Contributing factors to the inhibition of phagocytosis in hemodialyzed patients. Kidney Int 44: 208, 1993PubMedGoogle Scholar
  170. 170.
    Vanholder R, Ringoir S, Dhondt A, Hakim R, Waterloos MA, Van Lantschoot N, Gung A: Phagocytosis in uremic and hemodialysis patients: a prespective and cross sectional study. Kidney Int 39: 320, 1991PubMedGoogle Scholar
  171. 171.
    Descamps-Latscha B, Goldfarb B, Nguyen AT, Landais P, London G, Haeffner-Cavaillon N, Jacquot C, Herbelin A, Kazatchkine M: Establishing the relationship between complement activations and stimulation of phagocyte oxidative metabolism in hemodialized patients: a randomized prospective study. Nephron 59: 279, 1991PubMedCrossRefGoogle Scholar
  172. 172.
    Schopfer K, Douglas SD: Neutrophil function in children with kwashiorkor. J Lab Clin Med 88: 450, 1976PubMedGoogle Scholar
  173. 173.
    Thunberg BJ, Swamy AP, Cestero RVM: Cross-sectional and longitudinal nutritional measurements in maintenance hemodialysis patients. Am J Clin Nutr 34: 2005, 1981PubMedGoogle Scholar
  174. 174.
    Guarnieri G, Ranieri F, Lipartiti T, Spangaro F, Giuntini D, Faccini L, Toigo G, Legnani F, Raimondi A, Campanacci L: Protein-calorie malnutrition in hemodialysis patients. Int J Artif Organs 3: 143, 1980PubMedGoogle Scholar
  175. 175.
    Comty CM, Wathen RL, S2hapiro F: Protein metabolism in renal failure. Urology 1: 528, 1973PubMedGoogle Scholar
  176. 176.
    Mattern WD, Hak LJ, Lamanna RW, Teasley KM, Laffell MS: Malnutrition, altered immune function, and the risk of infection in maintenance hemodialysis patients. Am J Kidney Dis 1: 206, 1982PubMedGoogle Scholar
  177. 177.
    Glassock RJ: Nutrition, immunology, and renal disease. Kidney Int 74(Suppl 16): S194, 1983Google Scholar
  178. 178.
    Acchiardo SR, Moore LW, Latour PA: Malnutrition as the main factor in morbidity and mortality of hemodialysis patients. Kidney Int 24(Suppl 16): S199, 1983Google Scholar
  179. 179.
    Wolfson M, Strong CJ, Mintum D, Gray DK, Kopple JD: Nutritional status and lymphocyte function in maintenance hemodialysis patients. Am J Clin Nutr 39: 547, 1984PubMedGoogle Scholar
  180. 180.
    Collins A, Ma J, Umen A: Infectious and all-cause death rates in hemodialysis (HD) patients (PTS) are lower with a mean hematocrit (HCT) of 32% versus 26%. Abstract XIIth International Congress of Nephrology, Jerusalem, Israel, June 13–18, 1993Google Scholar
  181. 181.
    Churchill DN, Taylor W, Cook RJ, LaPlante P, Barre P, Cartier P, Fay WP, Goldstein MB, Jindal K, Mandin H et al.: Canadian hemodialysis morbidity study. Am J Kidney Dis 19:214, 1992PubMedGoogle Scholar
  182. 182.
    Hak LJ, Leffell MS, Lamanna RW, Teasley KM, Bazzarre CH, Mattem WD: Reversal of skin test anergy during maintenance hemodialysis by protein and caloric supplementation. Am J Clin Nutr 36: 1089, 1982PubMedGoogle Scholar
  183. 183.
    Casciato DA, McAdam LP, Kopple JD, Bluestone R, Goldberg LS, Clements PJ, Knutson DW: Immunologic abnormalities in hemodialysis patients: improvement after pyridoxine therapy. Nephron 38: 9, 1984PubMedGoogle Scholar
  184. 184.
    Antoniou LD, Shalhoub RJ, Schechter GP: The effect of zinc on cellular immunity in chronic uremia. Am J Clin Nutr 34: 1912, 1981PubMedGoogle Scholar
  185. 185.
    Antoniou LD, Shalhoub RJ: Zinc-induced enhancement of lymphocyte function and viability in chronic uremia. Nephron 40: 13, 1985Google Scholar
  186. 186.
    Briggs WA, Pedersen MM, Mahajan SK, Sillix DH, Prasad AS, McDonald FD: Lymphocyte and granulocyte function in zinc-treated and zinc-deficient hemodialysis patients. Kidney Int 21: 827, 1982PubMedGoogle Scholar
  187. 187.
    Opelz G, Sengar DP, Mickey MR, Terasaki PI: Effect of blood transfusions on subsequent kidney transplant. Transplant Proc 5: 253, 1973PubMedGoogle Scholar
  188. 188.
    Opelz G, Terasaki PI: Improvement of kidney-graft survival with increased numbers of blood transfusions. N Engl J Med 299: 799, 1978PubMedCrossRefGoogle Scholar
  189. 189.
    Bender BS, Curtis JL, Nagel JE, Chrest FJ, Kraus ES, Briefel GR, Adler WH: Analysis of immune status of hemodialyzed adults: association with prior transfusions. Kidney Int 26: 436, 1984PubMedGoogle Scholar
  190. 190.
    Fehrman I, Ringdén O, Möller E, Lundgren G, Goth CG: Is cell-mediated immunity in the uremic patient affected by blood transfusion? Transplant Proc 13: 164, 1981PubMedGoogle Scholar
  191. 191.
    Klatzmann D, Gluckman JC, Foucault C, Bensussan A, Assobga U, Duboust A: Suppression of lymphocyte reactivity by blood transfusions in uremic patients. I. Proliferative responses. Transplantation 35: 332, 1983PubMedGoogle Scholar
  192. 192.
    Kerman RH, Van Buren CT, Payne W, Flechner S, Agostino G, Conley S, Brewer E, Kahan BD: The influence of pretransplant blood transfusions from random dbnors on immune parameters affecting cadaveric allograft survival. Transplantation 36: 50, 1983PubMedGoogle Scholar
  193. 193.
    Smith MD, Hardy G, Williams JD, Coles GA: Suppressor cell numbers and activity in non-transfused renal dialysis patients. Clin Nephrol 20: 130, 1983PubMedGoogle Scholar
  194. 194.
    Smith MD, Williams JD, Coles GA, Salaman JR: The effect of blood transfusion on T-suppressor cells in renal dialysis patients. Transplant Proc 13: 181, 1981PubMedGoogle Scholar
  195. 195.
    Smith MD, Williams JD, Coles GA, Salaman JR: Blood transfusions, suppressor T cells, and renal transplant survival. Transplantation 36: 647, 1983PubMedCrossRefGoogle Scholar
  196. 196.
    Klatzmann D, Bensussan A, Gluckman JC, Foucault C, Dausset J, Sasportes M: Blood transfusions suppress lymphocyte reactivity in uremic patients. II. Evidence for soluble suppressor factors. Transplantation 36: 337, 1983PubMedCrossRefGoogle Scholar
  197. 197.
    Roy R, Lachance JG, Noel R, Grose JH, Beaudoin R: Improved renal allograft function and survival following nonspecific blood transfusions. I. Induction of soluble suppressor factors inhibiting the mitogenic response. Transplantation 41: 640, 1986PubMedGoogle Scholar
  198. 198.
    Kessler M, Hoen B, Mayeux D, Hestin D, Fontenaille C: Bacteremia in patients on chronic hemodialysis. Nephron 64: 95, 1993PubMedCrossRefGoogle Scholar
  199. 199.
    Goldman M, Vanherweghem JL: Bacterial infections in chronic hemodialysis patients: epidemiologic and pathophysiologic aspects. Adv Nephrol 19: 315, 1990Google Scholar
  200. 200.
    Keane WF, Shapiro FL, Raij L: Incidence and type of infections occurring in 445 chronic hemodialysis patients. Trans Am Soc Artif Intern Organs 23: 41, 1977PubMedGoogle Scholar
  201. 201.
    Maddy M, Keane WF: Unpublished observationsGoogle Scholar
  202. 202.
    Bradley JR, Evans DB, Calne RY: Long-term survival in haemodialysis patients. Lancet 1: 295, 1987PubMedGoogle Scholar
  203. 203.
    Charra B, Calemard E, Ruffet M, Chazot C, Terrat JC, Vanel T, Laurent G: Survival as an index of adequacy of dialysis. Kidney Int 41: 1286, 1992PubMedGoogle Scholar
  204. 204.
    Silins J, Fortier L, Mao Y, Posen G, Ugnat AM, Brancker A, Gaudette L, Wigle D: Mortality rates among patients with end-stage renal disease in Canada, 1981–86. Can Med Assoc J 141: 677, 1989Google Scholar
  205. 205.
    Keane WF, Collins AJ: Influence of comorbidity on mortality and morbidity in patients treated with hemodialysis. Am J Kidney Dis 24: 1010, 1994PubMedGoogle Scholar
  206. 206.
    Dobkin JF, Miller MH, Steigbigel NH: Septicemia in patients on chronic hemodialysis. Ann Intern Med 88: 28, 1978PubMedGoogle Scholar
  207. 207.
    Nsouli KA, Lazarus M, Schoenbaum SC, Gottlieb MN, Lowrie EG, Shocair M: Bacteremic infection in hemodialysis. Arch Intern Med 139: 1255, 1979PubMedGoogle Scholar
  208. 208.
    Cheesbrough JS, Finch RG, Burden RP: A prospective study of the mechanisms of infection associated with hemodialysis catheters. J Infect Dis 154: 579, 1986PubMedGoogle Scholar
  209. 209.
    Moss AH, McLaughlin MM, Lempert KD, Holley JL: Use of a silicone catheter with a dacron cuff for dialysis short-term vascular access. Am J Kidney Dis 12: 492, 1988PubMedGoogle Scholar
  210. 210.
    Gibson SP, Mosquera D: Five years experience with the Quinton Permcath for vascular access. Nephrol Dial Transplant 6: 269, 1991PubMedGoogle Scholar
  211. 211.
    Vanholder R, Hoenich N, Ringoir S: Morbidity and mortality of central venous catheter hemodialysis: a review of 10 years’ experience. Nephron 47: 274, 1987PubMedGoogle Scholar
  212. 212.
    Vanherweghem JL, Dhaene M, Goldman M, Stolear JC, Sabot JP, Waterlot Y, Serruys E, Thayse C: Infections associated with subclavian dialysis catheters: the key role of nurse training. Nephron 42: 116, 1986PubMedGoogle Scholar
  213. 213.
    Kaplowitz LG, Comstock JA, Landwehr DM, Dalton HP, Mayhall G: A prospective study of infections in hemodialysis patients: patient hygiene and other risk factors for infection. Infect Control Hosp Epidemiol 12: 534, 1988Google Scholar
  214. 214.
    Mulloy LL, Caruana RJ, Steele JCH, Wynn JJ: Polymicrobial bacteremia during long-term hemodialysis. South Med J 84: 594, 1991PubMedGoogle Scholar
  215. 215.
    Pezzarossi HE, Ponce de Leon S, Calva JJ, Lazo de la Vega SA, Ruiz-Palacios GM: High incidence of subclavian dialysis catheter-related bacteremias. Infect Control Hosp Epidemiol 7: 596, 1986Google Scholar
  216. 216.
    Kirmani N, Tuazon CU, Murray HW, Parrish AE, Sheagren JN: Staphylococcus aureus carriage rate of patients receiving long-term hemodialysis. Arch Intern Med 138: 1657, 1978PubMedGoogle Scholar
  217. 217.
    Goldblum SE, Ulrich JA, Goldman RS, Reed WP: Nasal and cutaneous flora among hemodialysis patients and personnel: quantitative and qualitative characterization and patterns of Staphylococcal carriage. Am J Kidney Dis 2: 281, 1982PubMedGoogle Scholar
  218. 218.
    Chow JW, Sorkin M, Goetz A, Yu VL: Staphylococcal infections in the hemodialysis unit: prevention using infection control principles. Infect Control Hosp Epidemiol 9: 531, 1988PubMedCrossRefGoogle Scholar
  219. 219.
    Yu VL, Goetz A, Wagener M, Smith PB, Rihs JD, Hanchett J, Zuravleff JJ: Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficacy of antibiotic prophylaxis. N Engl J Med 315: 91, 1986PubMedCrossRefGoogle Scholar
  220. 220.
    Boelaert JR, De Baere YA, Geernaert MA, Godard CA, Van Landuyt HW: The use of nasal mupirocin ointment to prevent Staphylococcus aureus bacteraemias in haemodialysis patients: an analysis of cost-effectiveness. J Hosp Infect 19: 41, 1991PubMedGoogle Scholar
  221. 221.
    Gordon SM, Oettinger CW, Bland LA, Oliver JC, Arduino MJ, Aguero SM, McAllister SK, Favero MS, Jarvis WR: Pyrogenic reactions in patients receiving conventional, high-efficiency, or high-flux hemodialysis treatments with bicarbonate dialysate containing high concentrations of bacteria and endotoxin. J Am Soc Nephrol 2: 1436, 1992PubMedGoogle Scholar
  222. 222.
    Beck-Sague CM, Jarvis WF, Bland LA, Arduino MJ, Aguero SM, Verosic G: Outbreak of gram-negative bacteremia and pyrogenic reactions in a hemodialysis center. Am J Nephrol 10:397, 1990PubMedGoogle Scholar
  223. 223.
    Longfield RN, Wortham WG, Fletcher LL, Nauscheutz WF: Clustered bacteremias in a hemodialysis unit: crosscontamination of blood tubing from ultrafiltrate waste. Infect Control Hosp Epidemiol 13: 160, 1992PubMedGoogle Scholar
  224. 224.
    Vanholder R, Vanhaecke E, Ringoir S: Waterborne pseudomonas septicemia. ASAIO Trans 36: M215, 1992Google Scholar
  225. 225.
    Latos DL, Stone WJ, Alford RH: Staphylococcus aureus bacteremia in hemodialysis patients. J Dial 1: 399, 1977PubMedGoogle Scholar
  226. 226.
    Francioli P, Masur H: Complications of Staphylococcus aureus bacteremia. Occurrence in patients undergoing long-term hemodialysis. Arch Intern Med 142: 1655, 1982PubMedGoogle Scholar
  227. 227.
    Quarles LD, Rutsky EA, Rostand SG: Staphylococcus aureus bacteremia in patients on chronic hemodialysis. Am J Kidney Dis 6: 412, 1985PubMedGoogle Scholar
  228. 228.
    Comty CM, Cohen SL, Shapiro FL: Pericarditis in chronic uremia and its sequels. Ann Intern Med 75: 173, 1971PubMedGoogle Scholar
  229. 229.
    Bailey GI, Hampers CL, Hager EB, Merrill JP: Uremic pericarditis: clinical features and management. Circulation 38: 582, 1968PubMedGoogle Scholar
  230. 230.
    Leonard A, Raij L, Shapiro FL: Bacterial endocarditis in regularly dialyzed patients. Kidney Int 4: 407, 1973PubMedGoogle Scholar
  231. 231.
    Goodman JS, Crews HD, Ginn HE, Koenig MG: Bacterial endocarditis as a possible complication of chronic hemodialysis. N Engl J Med 280: 876, 1969PubMedCrossRefGoogle Scholar
  232. 232.
    King LH Jr, Bradley KP, Shires DL Jr, Donohue JP, Glover JL: Bacterial endocarditis in chronic hemodialysis patients: a complication more common than previously suspected. Surgery 69: 554, 1971PubMedGoogle Scholar
  233. 233.
    Ribot S, Rothfeld D, Frankel HJ: Infectious endocarditis in maintenance hemodialysis patients. Am J Med Sci 264: 183, 1972PubMedGoogle Scholar
  234. 234.
    Keane WF, Raij LR: Host defenses and infectious complications in maintenance hemodialysis patients. in Replacement of Renal Function by Dialysis, 2nd Edition, edited by Drukker W, Parsons FM, Maher JF, The Hague, Martinus Nijhoff, 1983, p 646Google Scholar
  235. 235.
    Mathews M, Shen FH, Lindner A, Sherrard DJ: Septic arthritis in hemodialyzed patients. Nephron 25: 87, 1980PubMedGoogle Scholar
  236. 236.
    Parker MA, Tuazon CU. Cervical osteomyelitis. Infection due to Staphylococcus epidermidis in hemodialysis patients. JAMA 240: 50, 1978PubMedGoogle Scholar
  237. 237.
    Leonard A, Comty CM, Shapiro FL, Raij L: Osteomyelitis in hemodialysis patients. Ann Intern Med 78:651, 1973PubMedGoogle Scholar
  238. 238.
    Goodwin NJ, Castronuovo JJ, Friedman EA: Recurrent septic pulmonary embolization complicating maintenance hemodialysis. Ann Intern Med 71: 29, 1969PubMedGoogle Scholar
  239. 239.
    Levi J, Robson M, Rosenfeld JB: Septicaemia and pulmonary embolism complicating use of arteriovenous fistula in maintenance haemodialysis. Lancet 2: 288, 1970PubMedGoogle Scholar
  240. 240.
    Shapiro FL, Messner RP, Smith HT: Satellite hemodialysis. Ann Intern Med 69: 673, 1968PubMedGoogle Scholar
  241. 241.
    Aman LC, Levin NW, Smith DW: Hemodialysis access site morbidity. Proc Dial Transplant Forum 10: 277, 1980Google Scholar
  242. 242.
    Porter JA, Sharp WV, Walsh EJ: Complications of vascular access in a dialysis population. Curr Surg 42: 298, 1985PubMedGoogle Scholar
  243. 243.
    Winsett OE, Wolma FJ: Complications of vascular access for hemodialysis. South Med J 78: 513, 1985PubMedGoogle Scholar
  244. 244.
    Windus DW, Jendrisak MD, Delmez JA: Prosthetic fistula survival and complication in hemodialysis patients: effects of diabetes and age. Am J Kidney Dis 19: 448, 1992PubMedGoogle Scholar
  245. 245.
    Ralston AJ, Harlow GR, Jones DM, Davis P: Infections of Scribner and Brescia arteriovenous shunts. Br Med J 3: 408, 1971PubMedGoogle Scholar
  246. 246.
    Kinnaert P, Vereerstraeten P, Toussaint C, Van Geertruyden J: Nine years’ experience with internal arteriovenous fistulas for haemodialysis. Br J Surg 64: 242, 1977PubMedGoogle Scholar
  247. 247.
    Palder SB, Kirkman RL, Whittemore A2D, Hakim RM, Lazarus J1M, Tilney NL: Vascular access for hemodialysis. Ann Surg 202: 235, 1985PubMedGoogle Scholar
  248. 248.
    Zibari GB, Rohr MS, Landreneau MD, Bridges RM, De Vault GA, Petty FH, Costley KJ, Brown ST, McDonald JC: Complications from permanent hemodialysis vascular access. Surgery 104: 681, 1988PubMedGoogle Scholar
  249. 249.
    Vanderwerf BA, Rattazzi LC, Katzman KA, Schild AF: Three year experience with bovine graft arteriovenous (A-V) fistulas in 100 patients. Trans Am Soc Artif Intern Organs 21: 296, 1975PubMedGoogle Scholar
  250. 250.
    Yokoyama T, Bower R, Chinitz J, Schwartz A, Swartz C: Experience with 100 bovine arteriografts for maintenance hemodialysis. Trans Am Soc Artif Intern Organs 20: 328, 1974Google Scholar
  251. 251.
    Sabanayagam P, Schwartz AB, Soricelli RR, Lyons R, Chinitz J: A comparative study of 402 bovine heterografts and 225 reinforced expanded PTFE grafts as AVF in the ESRD patients. Trans Am Soc Artif Intern Organs 26: 88, 1980PubMedGoogle Scholar
  252. 252.
    Lilly L, Nghiem D, Mendez-Picon G, Lee HM: Comparison between bovine heterograft and expanded PTFE grafts for dialysis access. Am Surg 46: 694, 1980PubMedGoogle Scholar
  253. 253.
    Kaslow RA, Zellner SR: Infection in patients on maintenance hemodialysis. Lancet 2: 117, 1972PubMedGoogle Scholar
  254. 254.
    Dunea G, Domenico L, Gunnerson P, Winston-Willis F: A survey of permanent double lumen catheters in hemodialysis patients. ASAIO Trans 37: M276, 1991PubMedGoogle Scholar
  255. 255.
    Shusterman NH, Kloss K, Mullen JL: Successful use of double-lumen, silicone rubber catheters for permanent hemodialysis access. Kidney Int 35: 887, 1989PubMedGoogle Scholar
  256. 256.
    Bhat DJ, Tellis VA, Kohlberg Wl, Driscoll B, Veith FJ: Management of sepsis involving expanded polytetrafluoroethylene grafts for hemodialysis access. Surgery 87: 445, 1980PubMedGoogle Scholar
  257. 257.
    Nghiem DD, Schulak JA, Corry RJ: Management of the infected hemodialysis access grafts. Trans Am Soc Artif Intern Organs 29: 362, 1983Google Scholar
  258. 258.
    Morris AJ, Bilinsky RT. Prevention of staphylococcal shunt infections by continuous vancomycin prophylaxis. Am J Med Sci 261: 88, 1971Google Scholar
  259. 259.
    Bass HE, Singer E: Pulmonary changes in uremia. JAMA 144: 819, 1950Google Scholar
  260. 260.
    Bass HE, Greenberg D, Singer E: Pulmonary changes in uremia. JAMA 148:724, 1952Google Scholar
  261. 261.
    Hopps HC, Wissler RW: Uremic pneumonitis. Am J Pathol 31: 261, 1955PubMedGoogle Scholar
  262. 262.
    Rackow EC, Fein IA, Sprung C, Grodman RS: Uremic pulmonary edema. Am J Med 64: 1084, 1978PubMedGoogle Scholar
  263. 263.
    Goldstein E, Green GM: The effect of acute renal failure on the bacterial clearance mechanisms of the lung. J Lab Clin Med 68: 531, 1966PubMedGoogle Scholar
  264. 264.
    Johanson WG, Pierce AK, Sanford JP: Changing pharyngeal bacterial flora of hospitalized patients. Emergence of gram-negative bacilli. N Engl J Med 281: 1137, 1969PubMedCrossRefGoogle Scholar
  265. 265.
    Jadav SK, Sant SM, Acharya VN: Bacteriology of urinary tract infection in patients of renal failure undergoing dialysis. J Postgrad Med 23: 10, 1977PubMedGoogle Scholar
  266. 266.
    Saitoh H, Nakamura K, Hida M, Satoh T: Urinary tract infection in oliguric patients with chronic renal failure. J Urol 133: 990, 1985PubMedGoogle Scholar
  267. 267.
    Chaudhry A, Stone WJ, Breyer JA: Occurrence of pyuria and bacteriuria in asymptomatic hemodialysis patients. Am J Kidney Dis 21: 180, 1993PubMedGoogle Scholar
  268. 268.
    Rault R: Symptomatic urinary tract infections in patients on maintenance hemodialysis. Nephron 37: 82, 1984PubMedGoogle Scholar
  269. 269.
    Bennett WM, Craven R: Urinary tract infections in patients with severe renal disease. JAMA 236: 946, 1976PubMedGoogle Scholar
  270. 270.
    Pradhan RP, Katz LA, Nidus BD, Matalon R, Eisinger RP: Tuberculosis in dialyzed patients. JAMA 229: 798, 1974PubMedGoogle Scholar
  271. 271.
    Papadimitriou M, Memmos D, Metaxas P: Tuberculosis in patients on regular hemodialysis. Nephron 24: 53, 1979PubMedGoogle Scholar
  272. 272.
    Andrew OT, Schoenfeld P, Hopewell PC, Humphreys M: Tuberculosis in patients with end-stage renal disease. Am J Med 68: 59, 1980PubMedGoogle Scholar
  273. 273.
    Lundin AP, Adler AJ, Berlyne GM, Friedman EA: Tuberculosis in patients undergoing maintenance hemodialysis. Am J Med 67: 597, 1979PubMedGoogle Scholar
  274. 274.
    Rutsky EA, Rostand SG: Mycobacteriosis in parents with chronic renal failure. Arch Intern Med 140: 57, 1980PubMedGoogle Scholar
  275. 275.
    Sasaki S, Akiba T, Suenaga M, Tomura S, Yoshiyama N, Nakagawa S, Shoji T, Sasaoka T, Takeuchi J: Ten years’ survey of dialysis-associated tuberculosis. Nephron 24: 141, 1979PubMedGoogle Scholar
  276. 276.
    Belcon MC, Smith EKM, Kahana LM, Shimizu AG: Tuberculosis in dialysis patients. Clin Nephrol 17: 14, 1982PubMedGoogle Scholar
  277. 277.
    Mori MA, Leonardson G, Wclty TK: The benefits of isoniazid chemoprophylaxis and risk factors for tuberculosis among Oglala Sioux Indians. Arch Intern Med 152: 547 1992PubMedGoogle Scholar
  278. 278.
    Zeitlin J, Carvounis CP, Murphy RG, Tortora GT: Graft infection and bacteremia with Listeria monocytogenes in a patient receiving hemodialysis. Arch Intern Med 142: 2191, 1982PubMedGoogle Scholar
  279. 279.
    Woolridge TD, Cox JW: Graft infection and bacteremia. Arch Intern Med 143: 1070, 1983Google Scholar
  280. 280.
    Mossey RT, Sondheimer J: Listeriosis in patients with long-term hemodialysis and transfusional iron overload. Am J Med 79: 397, 1985PubMedGoogle Scholar
  281. 281.
    Van Cutsem J, Boelaert JR: Effects of deferoxamine, feroxamine and iron on experimental mucormycosis (zygomycosis). Kidney Int 36: 1061, 1989PubMedGoogle Scholar
  282. 282.
    Bárány P, Stenvinkel P, Nord CE, Bergström J: Clostridium difficile infection — a poor prognostic sign in uremic patients? Contrib Nephrol 38: 53, 1992Google Scholar
  283. 283.
    Leung ACT, Orange G, McLay A, Henderson S: Clostridium difficile-associated colitis in uremic patients. Clin Nephrol 24: 242, 1985PubMedGoogle Scholar
  284. 284.
    Aronsson B, Barany P, Nord CE, Nyström B, Stenvinkel P: Clostridium difficile-associated diarrhoea in uremic patients. Eur J Clin Microbiol 6: 352, 1987PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • Ann Rinehart
    • 1
  • Allan J. Collins
    • 2
  • William F. Keane
    • 3
  1. 1.Department of Medicine/Div. of NeprohologyHennepin County Medical CenterMinneapolisUSA
  2. 2.Regional Kidney Disease ProgramMinneapolisUSA
  3. 3.Division of Nephrology Department of Medicine Hennepin County Medical CenterUniversity of MinnesotaMinneapolisUSA

Personalised recommendations